LONG-TERM EFFECTS OF ORLISTAT ON EATING BEHAVIOR OF OBESITY PATIENTS
https://doi.org/10.15829/1560-4071-2015-9-37-43
Abstract
Aim. The assessment of the influence of long-term orlistat use on the eating behavior of obesity patients.
Material and methods. Totally 189 young patients studied with various grade of obesity, of those 107 women and 82 men at the age 18-44 y. o. Comparison group consisted of 34 healthy women and 31 healthy men (mean age — 39,21±0,46 y.). The anthropometric study performed, evaluation of food taking behavior, measurement of ghrelin level in the blood serum via ELISA method. Non-medication treatment (hypocaloric diet, physical exertion) was provided during 3 months. If no effect, then orlistat was prescribed 120 mg per os t. i.d. for 6-24 months.
Results. Among the studied patients, there were various types of eating behavior disorders found, mostly of emotiogenic and external types, nonbalanced of the food being taken. The decrease of body mass and mean value of WC was more prominent in patients with the III grade of obesity. Ghrelin level in the blood correlated with DMI and WC. The decrease of ghrelin in blood serum by from 10,4% in 6 months treatment to 46,3% in 24 months treatment witnessed sufficient saturation by the food if rational pattern of eating had been kept. After the end of treatment stability of following the rational pattern of food intake and healthy life style in the orlistat group less than 6 months was 59,5%, in 24 months — 97,8%.
Conclusion. Medication type of treatment, especially orlistat usage, is recommended to obesity patients as supportive to life style modification. Serious decrease of bodyweight is possible for the patients with obesity if long-term following healthy lifestyle.
About the Author
E. V. Korneeva
Surgut State University;
Surgut City Clinical Polyclinics №1, Khanty-Mansiysky Autonomic Region — Yugra
Russian Federation
Russian Federation
References
1. Voznesenskaja TG. The reasons of an inefficiency of treatment of obesity and the ways to overcome it. Problemy jendokrinologii. 2006; 52(6): 51-4. Russian (Вознесенская Т.Г. Причины неэффективности лечения ожирения и способы ее преодоления. Проблемы эндокринологии. 2006; 52 (6): 51-4).
2. Andrews ZB, Abizaid A. Neuroendocrine mechanisms that connect feeding behavior and stress. Front Neurosci. 2014; 8: 312.
3. Dickson SL, Egecioglu E, Landgren S, et al. The role of the central ghrelin system in reward from food and chemical drugs. Mol Cell Endocrinol. 2011; 340 (1): 80-7.
4. Uchida A, Zigman JM, Perello M. Ghrelin and eating behavior: evidence and insights from genetically-modified mouse models. Front Neurosci. 2013; 7: 121.
5. Barazzoni R, Zanetti M, Ferreira C, et al. Relationships between desacylated and acylated ghrelin and insulin sensitivity in the metabolic syndrome. J. Clin. Endocrinol. Metab.2007; 92 (10): 393.
6. Kirienkova, E. V. Metabolic and cardiovascular effects of ghrelin. Obesity and metabolizm. 2012; 1. Russian (Кириенкова, Е. В. Метаболические и сердечно-сосудистые эффекты грелина. Ожирение и метаболизм. 2012; 1).
7. Hosoda H, Kojima M, Kangawa K. Ghrelin and the regulation of food intake and energy balance. Mol. Interv. 2002; 2 (8): 494-503.
8. Tschop M, Wawarta R, Riepl RL, et al. Post-prandial decrease of circulating human ghrelin levels. J. of Endocrinological Investigation. 2001; 24 (6): 19-21.
9. Bondarenko IZ, Butrova SA, Goncharov NP. Treatment of morbid obesity in adult. National clinical guidelines. Obesity and metabolizm. 2011; 3. Russian (Бондаренко И. З., Бутр ова С. А., Гончаров Н. П. Лечение морбидного ожирения у взрослых. Национальные клинические рекомендации. Ожирение и метаболизм.2011; 3).
10. Joo JK, Lee KS. Pharmacotherapy for Obesity. Menopausal Med. 2014; 20(3): 90-6. 11. Shukla AP, Buniak WI, Aronne LJ. Treatment of obesity in 2015. J. Cardiopulm Rehabil Prev. 2015; 35(2): 81-92.
11. Vetter ML, Faulconbridge LF, Webb VL, et al. Behavioral and pharmacologic therapies for obesity. Nat.Rev.Endocrinol. 2010; 6(10): 578-88.
12. Van Strein T, Frijters JER, Bergers GPA et al.The Dutch Eating Behavior Questionnarie (DEBQ) for Assessment of Restrained, Emotional, and External Eating Behavior. Int. J. Eat. Disord. 1986; 5(2): 295-315.
13. Grilo CM, Marney A. White Orlistat with behavioral weight loss for obesity with versus without binge eating disorder: Randomized placebo-controlled trial at a community mental health center serving educationally and economically disadvantaged Latino. Behav Res Ther.2013; 51(3): 167-75.
14. Rucker D, Padwal R, Li S, et al. Long-term pharmacotherapy for obesity and overweight updated meta-analysis. British Medical Journal 2007; 335: 1194-9.
15. Svendsen M, Rissanen A, Richelsen B, et al. Effect of orlistat on eating behavior among participants in a 3-year weight maintenance trial. Obesity (Silver Spring). 2008; 16 (2): 327-33.
Review
For citations:
Korneeva E.V. LONG-TERM EFFECTS OF ORLISTAT ON EATING BEHAVIOR OF OBESITY PATIENTS. Russian Journal of Cardiology. 2015;(9):65-70. (In Russ.) https://doi.org/10.15829/1560-4071-2015-9-37-43
Views:
725
Email this article 